{"id":"cla-clarithro-lanso-amoxi","safety":{"commonSideEffects":[{"rate":"15–30%","effect":"Diarrhea"},{"rate":"10–20%","effect":"Nausea"},{"rate":"5–15%","effect":"Abdominal pain"},{"rate":"5–10%","effect":"Taste disturbance"},{"rate":"5–10%","effect":"Headache"},{"rate":"1–3%","effect":"Allergic reactions (amoxicillin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clarithromycin and amoxicillin are bactericidal antibiotics that inhibit H. pylori protein synthesis and cell wall integrity, respectively. Lansoprazole, a proton pump inhibitor, reduces gastric acid to create an optimal pH environment for antibiotic efficacy and promote ulcer healing. This triple combination is a standard regimen for H. pylori eradication.","oneSentence":"CLA is a triple-therapy combination that eradicates Helicobacter pylori through dual antibiotic action (clarithromycin and amoxicillin) plus acid suppression (lansoprazole).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:14.129Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication in peptic ulcer disease"},{"name":"H. pylori-associated gastritis"}]},"trialDetails":[{"nctId":"NCT02726269","phase":"PHASE3","title":"Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.","status":"COMPLETED","sponsor":"Asofarma de México S.A de C.V.","startDate":"2012-06","conditions":"Helicobacter Pylori Gastritis","enrollment":230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pylopac®, Medix, Mexico"],"phase":"phase_3","status":"active","brandName":"CLA (Clarithro+Lanso+Amoxi)","genericName":"CLA (Clarithro+Lanso+Amoxi)","companyName":"Asofarma de México S.A de C.V.","companyId":"asofarma-de-m-xico-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CLA is a triple-therapy combination that eradicates Helicobacter pylori through dual antibiotic action (clarithromycin and amoxicillin) plus acid suppression (lansoprazole). Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}